Biosimilars
Manufacturer Solutions
Helping your newest products thrive
AmerisourceBergen’s integrated commercialization
and distribution services help biosimilar manufacturers realize the potential
of this new and unique class of therapy. Our collaborative experts can help you
devise channel strategies and select tailored solutions that overcome barriers
to access and uptake.
Reaching patients where they are
Our extensive reach into health systems, physician practices, pharmacies and alternate sites of care makes your product accessible to patients and providers throughout the healthcare continuum. And our best-in-class distribution network ensures that your product reaches the right patients at the right time.
Our relationships span:
95%
U.S. HOSPITALS
65K+
SPECIALTY PHYSICIAN PRACTICES
34%
U.S. RETAIL PHARMACIES
Specialty physician GPO contracting
Connect with thousands of prescribers through
our market-leading specialty and oncology GPOs, which comprise a collective
purchasing power that is unrivaled in the industry. Members benefit from a
versatile contract portfolio, clinically integrated specialty pharmacy
services, practice management education and advocacy programs. Our
integrated model tightens the provider-patient relationship and allows
providers to more effectively guide treatment for better patient outcomes.
Improving product performance through targeted communication
Raise awareness of your newest product offerings through our CustomConnect℠ multi-channel marketing programs. CustomConnect seamlessly integrates your product message into customers' workflows so your communication stands out and gets recognized.
International commercialization capabilities
Innomar Strategies, part of AmerisourceBergen, offers a range of integrated services for commercializing biosimilars in Canada. From market access consulting to patient support programs and distribution services, our experienced teams deliver customized, scalable solutions to successfully launch your product in the Canadian market.
Expert perspectives
Are biosimilars the new generics?
Dave Picard, Senior Vice President, Global Generic Pharmaceuticals at AmerisourceBergen, speaks with Becker's Hospital Review about the current state of the industry and upcoming trends for this new class of therapy.
Read the article
